Engineering Bacteriophages as Versatile Biologics. Issue 4 (April 2019)

• Record Type: Journal Article
• Authors: Kilcher, Samuel; Loessner, Martin J.
• Is Part Of: Trends in microbiology. Volume 27:Issue 4(2019)
• Page Start: 355
• Page End: 367
• Publication Date: 2019-04
• Subjects: bacteriophage -- genome engineering -- synthetic biology -- phage therapy; Microbiology -- Periodicals; Infection -- Periodicals; Virulence (Microbiology) -- Periodicals; Infection -- Periodicals; Microbiology -- Periodicals; Virulence -- Periodicals; Microbiologie -- Périodiques; Infection -- Périodiques; Virulence (Microbiologie) -- Périodiques; Infection; Microbiology; Virulence (Microbiology); 579
• DOI: 10.1016/j.tim.2018.09.006
• Languages: English
• ISSNs: 0966-842X

Abstract

Abstract : Viruses of bacteria (bacteriophages or phages) are highly evolved nanomachines that recognize bacterial cell walls, deliver genetic information, and kill or transform their targets with unparalleled specificity. For a long time, the use of genetically modified phages was limited to phage display approaches and fundamental research. This is mostly because phage engineering has been a complex and time-consuming task, applicable for only a few well characterized model phages. Recent advances in sequencing technology and molecular biology gave rise to rapid and precise tools that enable modification of less-well-characterized phages. These methods will pave the way for the development of modular designer-phages as versatile biologics that efficiently control multidrug-resistant bacteria and provide novel tools for pathogen detection, drug development, and beyond. Highlights: The increasing prevalence of antibiotic-resistant pathogenic bacteria has sparked renewed interest in bacteriophage therapy. Synthetic biology methods allow design, straightforward construction, and testing of engineered bacteriophages that target both Gram-positive and Gram-negative bacteria. Phages with small genomes are easier to engineer using synthetic methods, while recombination-based approaches are currently the method of choice for larger phages. The efficiency, safety, and therapeutic suitability of phage-based antimicrobials can be specifically tailored through targeted phage engineering. In contrast to non-modified viruses, engineered phages offer intellectual property protection opportunities that may fuel the commercial implementation of phage therapy in many countries.